Business Description
MiNK Therapeutics is a New York-based clinical-stage company focused on developing ready-to-use cell therapies derived from a specialized immune cell type to fight cancer and immune-related conditions. Its lead treatment is being tested in multiple clinical trials targeting difficult-to-treat cancers, including advanced esophageal and gastric cancers, as well as severe respiratory illness. The company also has earlier-stage programs aimed at solid tumors, autoimmune diseases, and pediatric cancers, and works with several partners to expand its research. Founded in 2017 and operating as a subsidiary of Agenus Inc., MiNK Therapeutics changed its name from AgenTus Therapeutics in 2021.
